Selank · adverse-event profile · research use only
Selank side effects: the record is defined by a benzodiazepine comparison.
Selank's safety story is best told through the study that made its name. In a controlled Russian trial in patients with generalised anxiety disorder and neurasthenia, Selank was compared directly against the benzodiazepine medazepam (Medvedev et al., 2008) — and matched its anxiety reduction while producing none of the sedation, cognitive fog or dependence that define the benzodiazepine class. A later comparison against phenazepam (a more potent Russian benzodiazepine) reported comparable anxiolytic efficacy with a superior tolerability profile. That 'as effective, but without the benzo baggage' framing is the whole point of Selank's adverse-event profile, and it is a genuinely different story from most anxiolytics. The honest caveats mirror Semax's: the human evidence base is small, almost entirely Russian, typically 2–4 weeks long, and lacks Western randomized trials and long-term pharmacovigilance. Two specific negatives are worth recording because they are reassuring — published work notes no antibody (immunogenicity) formation and no disruption of glucose metabolism. Selank is one of the compounds Titan actually stocks, as a nasal spray. This page reproduces published literature as a research reference — not a human-use protocol or medical advice.
The defining finding: benzo efficacy without benzo side effects
The controlled trial versus medazepam (Medvedev et al., 2008; ~62 patients with GAD and neurasthenia) is the anchor of Selank's record: comparable anxiety reduction, but no sedation, no cognitive impairment and no dependence. A separate comparison against phenazepam reported similar efficacy with a better tolerability profile. Because the benzodiazepine class is defined by exactly those liabilities — sedation, cognitive dulling, tolerance, withdrawal — their consistent absence is the single most-cited safety point for Selank.
Semax vs Selank →The common reports are mild and route-linked
The adverse events reported with Selank are mild: nasal or sinus irritation from the intranasal route, transient headache, sore throat, and occasional nausea. As with any nasal peptide, the mucosa reacts first, so the local effects are the ones most often noticed. None of these are described as serious in the published abstracts, and no stimulant-type agitation or insomnia pattern is reported — consistent with an anxiolytic rather than a stimulant.
Dosage reference →Two reassuring negatives worth recording
Two specific non-findings distinguish Selank's record. First, no antibody formation (immunogenicity) has been reported — relevant because Selank is a synthetic analog of the immunomodulatory peptide tuftsin, so the question is a natural one to ask. Second, no disruption of glucose metabolism was noted — a useful contrast with Semax, where one review recorded a modest blood-glucose rise in diabetic patients. Recording negatives, not just positives, is part of an honest profile.
Selank half-life →No dependence or withdrawal signal
Across the published literature Selank is repeatedly described without documented tolerance, dependence or withdrawal — the properties that complicate long-term benzodiazepine use. Preclinical work adds no acute toxicity at studied doses and no histologic organ toxicity across species. This is the part of the record most consistent across sources, and the part that motivated its Russian approval for generalised anxiety disorder.
Research-use policy →The honest caveat: the data is limited and Russian
The most important thing to say is what is missing. The evidence is substantial by research-peptide standards but skewed: overwhelmingly Russian-language, single-institution, short in duration (2–4 weeks), and without completed Western randomized controlled trials or independent long-term pharmacovigilance. Read every clinical claim as 'Russian clinical data suggest,' not as an internationally replicated conclusion. The favourable picture is real but under-powered — treat it as favourable-but-incomplete.
Nootropic nasal peptides →Why identity verification still matters
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — a stabilised analog of the immunopeptide tuftsin. A truncated tuftsin fragment (as short as a 4-mer) or a mis-synthesised sequence can pass a bare HPLC purity number while being the wrong molecule, so identity is confirmed by mass-spectrometry against the full expected sequence, not a purity percentage alone. With a compound whose whole appeal is a clean tolerability profile, sourcing risk — identity, purity, sterility — is the real-world variable. Titan supplies Selank nasal spray with lot-matched, in-house release documentation available on request.
Selank nasal spray — $59.99 →The detail, in plain terms
The tolerability record, at a glance.
Points below are drawn from the published Selank literature (largely Russian clinical use, anchored by the medazepam-comparison trial) and review articles, reproduced as a research reference. The data set is small, short-duration and lacks independent long-term pharmacovigilance; treat the profile as favourable but incomplete.
- Defining comparison
- Matched benzodiazepine (medazepam) anxiolytic efficacy with no sedation, cognitive impairment or dependence (Medvedev 2008, ~62 patients); superior tolerability vs phenazepam.
- Nasal / sinus irritation
- Most common; local to the intranasal route; mild.
- Headache / sore throat / nausea
- Transient, mild, occasionally reported.
- Sedation / cognitive impairment
- Not reported — the point of the benzodiazepine comparison.
- Dependence / tolerance / withdrawal
- Not documented in the published literature.
- Immunogenicity
- No antibody formation reported — notable for a tuftsin analog.
- Glucose metabolism
- No disruption reported — a contrast with Semax's diabetic glucose note.
- Long-term safety
- Not established beyond ~2–4 weeks; largely Russian data; no completed Western RCTs.
- Identity check
- 7-mer sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) confirmed by MS; a truncated tuftsin fragment can hide behind a purity % alone.
Questions researchers ask
Before you order.
- What are the most common Selank side effects?
- The published record — mostly from Russian clinical use — describes mild, largely local effects: nasal or sinus irritation from the intranasal route, transient headache, sore throat and occasional nausea. No sedation, cognitive impairment or dependence is reported. These are research observations reproduced as a reference, not medical advice.
- Is Selank safe?
- The honest answer is 'favourable, but thinly studied in the West.' Its anchor study matched the benzodiazepine medazepam for anxiety reduction with no sedation, cognitive impairment or dependence, and published work notes no antibody formation and no glucose disruption. But the human evidence is small, largely Russian, typically 2–4 weeks long, and lacks Western randomized trials and long-term pharmacovigilance — so the profile should be read as favourable but incomplete rather than proven safe.
- How is Selank different from a benzodiazepine on side effects?
- That difference is the most-cited point in Selank's record. In a controlled trial versus medazepam it reduced anxiety comparably but without the sedation, cognitive impairment and dependence that define the benzodiazepine class, and a comparison versus phenazepam reported similar efficacy with better tolerability. Benzodiazepines are defined by exactly those liabilities, so their consistent absence is what makes Selank's tolerability profile distinctive.
- Does Selank affect blood sugar or the immune system?
- Published work reports no disruption of glucose metabolism — a useful contrast with Semax, where one review noted a modest glucose rise in diabetic patients — and no antibody (immunogenicity) formation, which is a natural question because Selank is a synthetic analog of the immunopeptide tuftsin. Both are reassuring non-findings from a limited literature, recorded here for completeness rather than as guarantees.
- How is Selank identity confirmed on a certificate?
- Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro — a stabilised analog of tuftsin. Because a truncated tuftsin fragment or a mis-synthesised sequence can pass a bare HPLC purity number while being the wrong molecule, identity is confirmed by mass spectrometry against the full expected sequence rather than a purity percentage alone. Titan provides lot-matched, in-house release documentation on request.
- Is Selank approved for human use?
- Selank has completed Phase III clinical trials in Russia and is approved there for generalised anxiety disorder, but it is not FDA-approved in the United States. Titan Peptide Lab supplies Selank nasal spray strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The tolerability data here summarises published literature and is not medical or dosing advice.